Botulinum toxin treatments of neurological and neuropsychiatric disorders

Abstract

Methods for preventing or treating neuropsychiatric disorder and/or a neurological disorder including a neurological disorder mediated by the thalamus. Neuropsychiatric disorders and/or a neurological disorders, including a thalamically mediated disorder can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating a neurological disorder and/or a neuropsychiatric disorder.

I claim: 
     
         1 . A method for treating a neuropsychiatric disorder, the method comprising administering a medicament comprising a botulinum toxin to a trigeminal nerve of a patient with a neuropsychiatric disorder, thereby treating the neuropsychiatric disorder. 
     
     
         2 . The method of  claim 1 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C 1 , D, E, F and G. 
     
     
         3 . The method of  claim 1 , wherein the botulinum toxin is a botulinum toxin type A. 
     
     
         4 . The method of  claim 1 , wherein the botulinum toxin is administered subdermally. 
     
     
         5 . The method of  claim 1 , wherein the botulinum toxin is administered non-intramuscularly. 
     
     
         6 . The method of  claim 1 , wherein the medicament is administered in an amount of between about 1 unit and about 3000 units of botulinum toxin. 
     
     
         7 . The method of  claim 1 , wherein the botulinum toxin is administered by topical or subcutaneous administration. 
     
     
         8 . The method of  claim 1 , wherein the neurospyschiatrid disorder is selected from the group consisting of schizophrenia, depression, mania, or combinations thereof. 
     
     
         9 . The method of  claim 1 , wherein the medicament is administered to a trigeminal sensory nerve of the patient. 
     
     
         10 . The method of  claim 8 , wherein the trigeminarl sensory nerve is selected from the group consisting of an ophthalmic nerve, maxillary nerve, mandibular nerve, supra orbital nerve, supra trochlear nerve, infraorbital nerve, lacrimal nerve, nasociliary nerve, superior alveolar nerve, buccal nerve, lingual nerve, inferior alveolar nerve, mental nerve, an auriculotemporal nerve, lesser occipital nerve and a greater occipital nerve. 
     
     
         11 . A method for reducing the occurrence of a neuropsychiatric disorder, the method comprising administering a medicament comprising a botulinum toxin non-intramuscularly to a trigeminal nerve of a patient with a neuropsychiatric disorder, thereby reducing the occurrence of the neurospychiatric disorder. 
     
     
         12 . The method of  claim 11 , wherein the botulinum toxin is a botulinum toxin type A. 
     
     
         13 . The method of  claim 11 , wherein the botulinum toxin is administered subdermally. 
     
     
         14 . The method of  claim 11 , wherein the medicament is administered in an amount of between about 1 unit and about 3000 units of botulinum toxin. 
     
     
         15 . The method of  claim 11 , wherein the botulinum toxin is administered by topical or subcutaneous administration. 
     
     
         16 . The method of  claim 11 , wherein the neurospyschiatrid disorder is selected from the group consisting of schizophrenia, depression, mania, or combinations thereof. 
     
     
         17 . The method of  claim 11 , wherein the medicament is administered to a trigeminal sensory nerve of the patient.